NCT06802042 Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women
| NCT ID | NCT06802042 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Functional Constipation (FC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-09 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-01-09 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Constipation (constipation) is a common clinical symptom, including difficulty in defecation and / or reduced frequency of defecation, dry and hard stool, difficulty in defecation, feeling of inexhaustible defecation, feeling of anorectal obstruction, time-consuming defecation and need for auxiliary defecation. Reduced defecation means defecation less than 3 times a week.Constipation is very common during pregnancy, and studies have found that the incidence of constipation in pregnant women is as high as 40%. Among them, the prevalence of functional constipation in the early, middle, late and postpartum pregnancies is 35%, 39%, 21% and 17% respectively, with the highest in the early and middle pregnancies.Constipation can increase the psychological burden of pregnant women and affect their quality of life. Long-term severe constipation can also induce or aggravate hemorrhoids. Severe constipation can induce uterine contractions, which will adversely affect the pregnancy outcome of pregnant women.Studies have found that there is a difference in the abundance of intestinal flora between patients with constipation during pregnancy and pregnant women without digestive tract diseases.Although microecological preparations are not front-line drugs for the treatment of chronic constipation, they can promote intestinal peristalsis and the recovery of gastrointestinal motility by regulating the imbalance of intestinal flora. More and more researchers recommend them as long-term adjuvant drugs for chronic constipation. Probiotics are a type of microecological preparation, which refers to living microorganisms that can have beneficial health effects on the host after ingesting a sufficient amount.It is relatively safe to supplement probiotics during pregnancy.Our research team found a probiotic strain, Lactobacillus reuteri DSM17938+, which has no significant difference in improving constipation symptoms in patients with constipation compared with lactulose, and is even more effective than lactulose in alleviating abdominal pain and flatulence symptoms.However, clinical studies proving that Lactobacillus reuteri DSM17938 + is effective on constipation are generally concentrated abroad, and mainly focus on infants and young children, children, adults\] or intestinal colic. Data on maternal population in China is lacking.
Eligibility Criteria
Inclusion Criteria: * (1) Pregnant women, age ≥18 years and \<40 years old, and gestational age \<28 weeks; (2) Must meet two or more of the following symptoms (Refer to the Roman IV standard): * It is difficult to defecate at least 25% of the time; * It is lumpy or hard stool at least 25% of the time; * It is not enough to defecate at least 25% of the time; * It is at least 25% of the time that there is anorectal obstruction or obstruction in defecation; * It requires manual assistance at least 25% of the time; ⑥It is spontaneous defecation less than 3 times a week. At the same time, loose stools rarely occur when no laxatives are used, which does not meet the diagnostic criteria of irritable bowel syndrome (IBS). The symptoms in the past 2 weeks have met the above diagnostic criteria. (3) Pregnant women receive and follow high-protein and high-fiber dietary guidance during the first trimester. (4) There were no other complications. (5) No medication was used to interfere with constipation symptoms. Exclusion Criteria: * (1) Non-pregnant women, age \<18 years or ≥40 years old, and gestational age ≥28 weeks; (2) Constipation caused by intestinal and systemic organic factors, drugs and other reasons, or concurrent with other non-constipation intestinal diseases; (3) History of use of antibiotics, probiotics, prebiotics, etc. in the past 2 weeks; (4) Pregnant women with thyroid disease, diabetes, hypertension, obesity, overweight or any metabolic disease.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06802042 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Functional Constipation (FC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06802042 currently recruiting?
Yes, NCT06802042 is actively recruiting participants. Contact the research team at sunyin@pumch.cn for enrollment information.
Where is the NCT06802042 trial being conducted?
This trial is being conducted at Beijing, China, Wenzhou, China.
Who is sponsoring the NCT06802042 clinical trial?
NCT06802042 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 40 participants.